BOSTON – May 15, 2007 – While drug developers over the past six years have stepped up the number of postmarketing studies they conduct on newly approved medicines, sponsors feel that those studies have contributed little to their understanding of safety, efficacy, or quality, a recently completed assessment by the Tufts Center for the Study of Drug Development shows. According to a Tufts CSDD survey, 68% of clinical study sponsors and 79% of non-clinical study sponsors said results contributed either marginally or not at all to their understanding of the safety, efficacy, or quality of their product. >>> Discuss This Story